Chronic Pulmonary Hypertension Market Size in the 7MM was ~USD 28,290 million in 2023, estimates DelveInsight

DelveInsight's "Chronic Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Chronic Pulmonary Hypertension market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Chronic Pulmonary Hypertension Market is an evolving segment of the global healthcare landscape, driven by the increasing Chronic Pulmonary Hypertension prevalence of the disorder and the continuous development of innovative treatment options. The Chronic Pulmonary Hypertension market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

Discover Key Insights into the Chronic Pulmonary Hypertension Market with DelveInsight's In-Depth Report @ Chronic Pulmonary Hypertension Market Size [https://www.delveinsight.com/sample-request/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chronic Pulmonary Hypertension Market Report

* In November 2024:- Merck Sharp & Dohme LLC- A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease. Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take MK-5475 can walk farther in 6 minutes at Week 24 compared to people who take placebo.
* The total prevalent cases of Chronic Pulmonary Hypertension in the US are expected to increase with a significant CAGR by 2034, from around 17,910 thousand cases in 2023 in the US.
* Among the European countries, Germany (26%) had the highest prevalent population of Chronic Pulmonary Hypertension, followed by the UK in 2023. On the other hand, Spain had the least diagnosed prevalent population around 15% of Chronic Pulmonary Hypertension in the same year.
* However, the prevalent cases of Chronic Pulmonary Hypertension are expected to decrease in Germany and Japan attributed to decrease in country population and other factors.
* In Japan, among prevalent cases of Chronic Pulmonary Hypertension, most cases were of Group II Chronic Pulmonary Hypertension (~5,724 thousand) in 2023. While least were in Group I Chronic Pulmonary Hypertension around 54 thousand in the same year.
* The Chronic Pulmonary Hypertension prevalent cases were segmented based on age in four agegroups
* Assessments as per DelveInsight's analysts show that the majority of cases of Chronic Pulmonary Hypertension are occupied by females in comparison to males. There were approximately ~6,806 thousand male and ~11,104 thousand female cases of Chronic Pulmonary Hypertension in 2023 in the US.
* The leading Chronic Pulmonary Hypertension Companies such as Attgeno, Insmed Incorporated, Merck Sharp & Dohme Corp., United Therapeutics, Actelion, Bayer, Merck Sharp & Dohme LLC, Epix Pharmaceuticals, Inc., Dong-A PharmTech Co., Ltd., Janssen, LP, and others
* Promising Chronic Pulmonary Hypertension Therapies such as Supernitro, Treprostinil Palmitil Inhalation Powder, MK-5475, Remodulin, bosentan, Riociguat (Adempas, BAY63-2521), PRX-08066, Udenafil, Macitentan, and others.

Stay ahead in the Chronic Pulmonary Hypertension Therapeutics Market with DelveInsight's Strategic Report @ Chronic Pulmonary Hypertension Market Outlook [https://www.delveinsight.com/sample-request/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Pulmonary Hypertension Epidemiology Segmentation in the 7MM

* Total Chronic Pulmonary Hypertension Prevalent Cases
* Chronic Pulmonary Hypertension Group-specific Prevalent Cases
* Chronic Pulmonary Hypertension Group-specific Prevalent Cases
* Chronic Pulmonary Hypertension Age-specific Prevalent Cases

Download the report to understand which factors are driving Chronic Pulmonary Hypertension epidemiology trends @ Chronic Pulmonary Hypertension Prevalence [https://www.delveinsight.com/sample-request/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Pulmonary Hypertension Marketed Drugs

* ADEMPAS (riociguat): Bayer

ADEMPAS (riociguat) is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). Riociguat has a dual mode of action. It sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding.

Chronic Pulmonary Hypertension Emerging Drugs

* CS1: Cereno Scientific AB

The drug candidate CS1 is a HDAC inhibitor with a new advanced reformulation of valproic acid (VPA) and acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic, and pressure-relieving properties. CS1 is being developed as a treatment for the rare disease PAH with the aim of offering patients a better and safer disease-modifying drug. CS1's unique efficacy profile fits well with the pathogenetic mechanisms of the rare disease PAH and is believed to be able to address today's major unmet need for better treatment alternatives.

Get In-Depth Knowledge on Chronic Pulmonary Hypertension Market Trends and Forecasts with DelveInsight @ Chronic Pulmonary Hypertension Treatment Market [https://www.delveinsight.com/sample-request/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Pulmonary Hypertension Market Outlook

Phosphodiesterase-5 (PDE-5) inhibitors such as Sildenafil and Tadalafil are efficient in providing the antiproliferative effects on vascular smooth muscle cells and inducing vasodilation. Endothelin receptor antagonists such as Ambrisentan, Bosentan and Macitentan exertvasoconstrictor and mitogenic effects on the pulmonary vascular smooth muscles. Nifedipine, diltiazem, or amlodipine are the most commonly recommended calcium channel blockers being used for the treatment of Pulmonary Arterial Hypertension. Prostacyclins such as epoprostenol, treprostinil, iloprost are recommended for improving the functional capacity and survival rate among the patients of Pulmonary Hypertension. Apart from the aforesaid, IP prostacyclin receptor agonists are also used in the treatment of Chronic PH. They bind selectively to the IP receptor and follow the prostacyclin pathway.

Scope of the Chronic Pulmonary Hypertension Market Report

* Coverage- 7MM
* Chronic Pulmonary Hypertension Companies- Attgeno, Insmed Incorporated, Merck Sharp & Dohme Corp., United Therapeutics, Actelion, Bayer, Merck Sharp & Dohme LLC, Epix Pharmaceuticals, Inc., Dong-A PharmTech Co., Ltd., Janssen, LP, and others
* Chronic Pulmonary Hypertension Therapies- Supernitro, Treprostinil Palmitil Inhalation Powder, MK-5475, Remodulin, bosentan, Riociguat (Adempas, BAY63-2521), PRX-08066, Udenafil, Macitentan, and others.
* Chronic Pulmonary Hypertension Market Dynamics: Chronic Pulmonary Hypertension Market Drivers and Barriers
* Chronic Pulmonary Hypertension Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight's Comprehensive Chronic Pulmonary Hypertension Market Report @ Chronic Pulmonary Hypertension Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1 Key Insights

2 Report Introduction

3 Chronic Pulmonary Hypertension Market Overview at a Glance

4 Epidemiology and Market Forecast Methodology of Chronic Pulmonary Hypertension

5 Executive Summary of Chronic Pulmonary Hypertension

6 Key Events

7 Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Drugs

11 Emerging Drugs

12 Chronic Pulmonary Hypertension: Seven Major Market Analysis

13 KOL Views

14 SWOT Analysis

15 Unmet Needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-pulmonary-hypertension-market-size-in-the-7mm-was-usd-28290-million-in-2023-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.